New targeted therapies for treatment of thrombosis in antiphospholipid syndrome (Q36998932)

17 August 2017

1 reference

title

New targeted therapies for treatment of thrombosis in antiphospholipid syndrome (English)

1 reference

17 August 2017

1 reference

Silvia S Pierangeli

1

1 reference

17 August 2017

Mariano E Vega-Ostertag

series ordinal

2

1 reference

17 August 2017

Emilio B González

series ordinal

3

1 reference

17 August 2017

publication date

13 November 2007

1 reference

Expert Reviews in Molecular Medicine

17 August 2017

published in

1 reference

17 August 2017

volume

9

1 reference

17 August 2017

issue

30

1 reference

17 August 2017

page(s)

1-15

1 reference

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Toll-like receptors: critical proteins linking innate and acquired immunity

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Complement C3 activation is required for antiphospholipid antibody-induced fetal loss

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Syndrome of the black swan

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Nuclear factor kappaB mediates a procoagulant response in monocytes during extracorporeal circulation

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Alveolar and serum antiphospholipid antibodies in acute respiratory distress syndrome associated with catastrophic antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

NF-kappaB activation plays a role in superoxide-mediated cerebral endothelial dysfunction after hypoxia/reoxygenation

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Unusual manifestations of the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Clinical relevance of antiprothrombin antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

The long-term prognosis of renal transplantation in patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Annexin A2 mediates endothelial cell activation by antiphospholipid/anti- 2 glycoprotein I antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

The search for physiological substrates of MAP and SAP kinases in mammalian cells

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Sneddon's syndrome and phospholipid antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

E-Selectin mediates pathogenic effects of antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Transverse myelitis in patients with antiphospholipid antibodies--the importance of early diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Gene-expression patterns predict phenotypes of immune-mediated thrombosis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

NF-kappaB: Holy Grail for rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Monocyte adhesion and transmigration induce tissue factor expression: role of the mitogen-activated protein kinases.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

New insights into the role of nuclear factor-KB, a ubiquitous transcription factor in the initiation of diseases

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Mechanisms of autoantibody-mediated thrombosis

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

"Black swan in the kidney": renal involvement in the antiphospholipid antibody syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000506

7 January 2021

10.1017/S1462399407000506

Identifiers

DOI

0 references

1 reference